Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023634 · ClinicalTrials.gov registry record · Phase 1
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
A Phase 1 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00023634 is a Phase 1 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 14 participants.
The verdict
NCT00023634, a Phase 1 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying two different vaccines to treat patients who have gastric, prostate, or ovarian cancer.
Interventions
- BIOLOGICAL KLH
- BIOLOGICAL GMCSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2001-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023634
The ClinicalTrials.gov registry entry for NCT00023634 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KLH is the first listed.
NCT00023634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023634 about?
NCT00023634 is a clinical study titled "S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer". RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill cancer cells. PURPOSE: This phase I trial is studying two different vaccines to treat patients who have gastric, prostate, or ovarian cancer.
What is the current status of trial NCT00023634?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2001-06. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00023634?
The interventions under investigation include: KLH (BIOLOGICAL), GMCSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT00023634?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.